At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 Jan 1997 No-Development-Reported for Inflammation (PO)